At a glance
| Chemical family | An antineoplastic (chemotherapy) drug — a second-generation platinum agent and analog of cisplatin |
| CAS number | 41575-94-4 |
| Classification | A NIOSH-listed hazardous drug; genotoxic. Not classified by IARC as a carcinogen — unlike cisplatin (Group 2A). Often mislabelled "Group 2A," which is incorrect for carboplatin |
| Where you encounter it | Only in a home where someone is being treated: excreted in urine and other fluids, depositing on toilet/bathroom surfaces, bedding and laundry |
| Sleep micro-environment relevance | A household caregiver- and laundry-hygiene concern — contaminated bedding and surfaces, not the mattress — for a limited period after each dose |
| Activated carbon capture | Not relevant — a surface/laundry-residue issue managed by gloves, separate laundering and cleaning, not air filtration |
Regulatory & certification status
Where Carboplatin stands across the major regulatory systems and the certifications a bedroom product might carry. Each row links to the governing instrument; where a jurisdiction has no specific measure, that is stated plainly rather than left blank.
| European Union | No harmonised CLP Annex VI entry for carboplatin (EC 255-446-0) could be confirmed from a primary source, and no REACH SVHC Candidate List, Authorisation List (Annex XIV) or restriction (Annex XVII) entry was identified; as a finished medicinal product it sits largely outside REACH's industrial scope. Carboplatin is, like other antineoplastics, handled as a hazardous medicinal product for occupational safety under the EU's Carcinogens, Mutagens and Reprotoxic Substances Directive framework (Directive 2004/37/EC, as amended by Directive (EU) 2022/431); the Commission's indicative list of hazardous medicinal products (C/2025/1150) sits within that framework, but its naming of carboplatin could not be independently verified here because the EUR-Lex text was not machine-readable. Treated as partial pending direct confirmation of that listing and of any registrant C&L Inventory self-classification. Regulatory — EUR-Lex |
| United States | Under California Proposition 65, carboplatin (CAS 41575-94-4) is listed for developmental toxicity (a reproductive-toxicity endpoint), with a listing date of 1 July 1990 via the "Formally Required" (FR) mechanism. It is not listed by Proposition 65 as a carcinogen — the official list carries only the single developmental-toxicity entry. As an FDA-approved chemotherapy drug, carboplatin is regulated under the Federal Food, Drug, and Cosmetic Act; no TSCA risk evaluation or action for carboplatin was identified. Regulatory — OEHHA |
| Canada | No CEPA Schedule 1 (List of Toxic Substances) listing and no Chemicals Management Plan / DSL assessment for carboplatin was identified; as a pharmaceutical it is regulated under the Food and Drugs Act rather than CEPA's industrial-chemical framework. No specific restriction identified. Regulatory — Government of Canada · Canada |
| Australia | AICIS (and the IChEMS framework) regulate industrial chemicals; carboplatin is a therapeutic good regulated by the TGA, not AICIS. No AICIS evaluation or IChEMS listing for carboplatin was identified. No specific restriction identified. Regulatory — AICIS |
| United Kingdom | No GB-specific mandatory (harmonised) classification under GB CLP and no UK REACH restriction or authorisation entry for carboplatin was identified; Great Britain inherited the retained EU CLP position, which carries no confirmed harmonised Annex VI entry for this substance. No specific restriction identified. Regulatory — HSE |
| Certifications | CertiPUR-US, OEKO-TEX Standard 100 and UL GREENGUARD/GREENGUARD Gold are foam, textile and low-VOC-emissions programmes whose published criteria target polyurethane-foam, textile and consumer-product chemistry (e.g. CertiPUR-US screens for prohibited flame retardants, heavy metals, phthalates and CFCs; OEKO-TEX's Restricted Substances List covers dyes, formaldehyde, APEOs, PFCs and heavy metals). None of these criteria name carboplatin, an intravenous platinum chemotherapy drug with no pathway into mattresses or textiles. Carboplatin is therefore outside the scope of all three programmes rather than specifically passed or restricted by them. Industry — CertiPUR-US · OEKO-TEX |
| The 72-hour test window | Not applicable. Carboplatin is a non-volatile, water-soluble platinum coordination compound (an intravenous chemotherapy drug, not a material additive), so it has effectively no vapour pressure to off-gas and would not appear in a short ~72-hour VOC chamber test. It is not a sleep-environment emission in the first place. Inferred — from the compound's volatility/emission profile versus the VOC focus of short chamber tests |
What it is
Carboplatin is a second-generation platinum chemotherapy drug, developed as a gentler analog of cisplatin — it keeps the platinum-DNA mechanism but is easier on the kidneys and nerves, which is why it is widely used for ovarian, lung and other cancers. As with everything in this family, it is first and foremost an important medicine.
Its place here turns on a precise point of classification. Carboplatin is genotoxic and is listed by NIOSH as a hazardous drug requiring careful handling. Regulatory — NIOSH lists carboplatin among hazardous antineoplastic drugs requiring safe-handling precautions But it has not been classified by IARC as a carcinogen — a meaningful difference from its parent cisplatin, which is an IARC Group 2A compound. Inferred — carboplatin is absent from the IARC carcinogen classifications that include cisplatin; the common "Group 2A" label is a misattribution and is corrected here Calling carboplatin a "Group 2A carcinogen," as some summaries do, is simply wrong, and this Atlas does not repeat the error.
How it relates to the bedroom
The household route: excretion onto surfaces and bedding
Carboplatin reaches the sleep environment exactly as its platinum parent does — through the patient's excreta. It is cleared in urine for days after treatment, and hospital monitoring finds antineoplastic drugs across patient areas, with the highest levels on the floors of patient lavatories, explicitly tied to the handling of patients' urine. That study measured cyclophosphamide and ifosfamide specifically, not carboplatin, so this is class-level supporting evidence rather than carboplatin-specific data. Inferred — extrapolated from antineoplastic-class surface monitoring; Hedmer et al. 2008 did not assay carboplatin/platinum The drugs are not only on surfaces but get into people: most nurses studied carried measurable internal antineoplastic-drug contamination, some of it from skin contact with contaminated surfaces rather than direct handling — again a class-level finding, not carboplatin-specific. Inferred — extrapolated from antineoplastic-class biomonitoring; Villa et al. 2021 did not assay carboplatin/platinum
The bedding link is specific to the drug class rather than to carboplatin itself. Among the tasks that most strongly predicted picking up these drugs, changing the sheets or making the bed of a treated patient stood out — but the drugs biomonitored were methotrexate, cyclophosphamide, ifosfamide, a 5-fluorouracil metabolite, and doxorubicin, not carboplatin. Inferred — extrapolated from antineoplastic-class biomonitoring; Villa et al. 2023 did not assay carboplatin/platinum In a home, that is the family caregiver's job — the exposure this page exists to address.
Keeping it in proportion
The calibration is the same as for the rest of the family. Carboplatin is a genotoxic hazardous drug, so reasonable precautions are warranted — but documented third-party exposures are low-level traces, and the response is sensible hygiene rather than alarm. Inferred — household third-party exposure is low-level; precaution follows the ALARA principle The drug is doing essential work for the patient; the caregiver's task is to keep their own incidental contact low during the short window after each dose.
What the research says
- Not an IARC-classified carcinogen. Genotoxic and NIOSH-hazardous, but not Group 2A — unlike cisplatin. Inferred — corrected from a common misattribution
- Excreted and surface-deposited. Antineoplastic drugs (class-level, not carboplatin-specific) found on patient-lavatory floors, tied to handling of patients' urine. Inferred — Hedmer et al. 2008 assayed cyclophosphamide/ifosfamide, not carboplatin
- Reaches people via surfaces. Most studied nurses internally contaminated with a panel of antineoplastic drugs, partly from skin contact — a class-level finding. Inferred — Villa et al. 2021 did not assay carboplatin/platinum
- Bedding is a real route. Sheet-changing/bed-making strongly associated with internal contamination in nurses biomonitored for other antineoplastic drugs. Inferred — Villa et al. 2023 assayed methotrexate/cyclophosphamide/ifosfamide/5-FU/doxorubicin, not carboplatin
What helps reduce it
Follow your care team's home-chemo precautions. Generally for about a week after each dose. Inferred — standard home-chemotherapy caregiver guidance
Glove up and launder separately. Disposable gloves for soiled linens and fluids; wash contaminated bedding apart from other laundry with an extra rinse. Inferred — extrapolated from antineoplastic-class handling guidance; Villa et al. 2023 studied other antineoplastic drugs, not carboplatin specifically
Manage the bathroom. Close the lid before flushing and clean surfaces — the documented hot spots for the antineoplastic-drug class. Inferred — extrapolated from antineoplastic-class surface monitoring; Hedmer et al. 2008 studied other antineoplastic drugs, not carboplatin specifically
What does NOT help
- Replacing the mattress. The drug is a transient excreted residue, not a bedding ingredient; hygiene and laundering address it. Inferred
- Mislabelling it a Group 2A carcinogen. That overstates the classification; precautions rest on genotoxicity and hazardous-drug status. Inferred
Open research questions
- The real magnitude of any health risk to home caregivers from low-level contact with excreted platinum drugs. Speculation
- Whether carboplatin's gentler toxicity profile relative to cisplatin translates to any difference in third-party exposure risk. Speculation
The Embr Exposure Ledger: Carboplatin
One chemical, several public questions, answered from independent datasets and joined here — the environment it shows up in, the body burden it carries, how it is regulated, and what actually reduces it.
Detection and body-burden figures are occurrence data, not a personal measurement or a health diagnosis. Part of the Embr Exposure Ledger — an open, cross-dataset chemical join (download the data), reusable with attribution.
Citations
- Hedmer M, et al. (2008). Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. Int. Arch. Occup. Environ. Health. Assayed cyclophosphamide and ifosfamide (not carboplatin); drugs found on most surfaces, highest on patient-lavatory floors, tied to handling patients' urine — cited here as class-level route evidence, not carboplatin-specific data. Via Consensus. DOI 10.1007/s00420-007-0284-y Peer-reviewed
- Villa A, et al. (2021). Nurses' internal contamination by antineoplastic drugs in hospital centers. Int. Arch. Occup. Environ. Health. Biomonitored a panel of antineoplastic drugs (not carboplatin); 60.8% of nurses internally contaminated, some from skin contact with contaminated surfaces — cited here as class-level route evidence, not carboplatin-specific data. Via Consensus. DOI 10.1007/s00420-021-01706-x Peer-reviewed
- Villa A, et al. (2023). Factors associated with internal contamination of nurses by antineoplastic drugs. Int. J. Hyg. Environ. Health. Biomonitored methotrexate, cyclophosphamide, ifosfamide, a 5-fluorouracil metabolite, and doxorubicin (not carboplatin); changing sheets / making the bed of a treated patient strongly associated with internal contamination — cited here as class-level route evidence, not carboplatin-specific data. Via Consensus. DOI 10.1016/j.ijheh.2023.114264 Peer-reviewed
Frequently asked questions
What is carboplatin?
Carboplatin is a platinum-based chemotherapy drug — the gentler, second-generation analog of cisplatin, developed to keep much of cisplatin's anticancer power with less kidney and nerve toxicity. It is widely used for ovarian, lung and other cancers. Like the rest of this family, it is a valuable cancer treatment, and it belongs in a bedroom atlas only because of what happens after a dose: the drug is excreted, and traces reach surfaces and bedding.
Is carboplatin a carcinogen?
Worth stating precisely. Carboplatin is a genotoxic, NIOSH-listed hazardous drug and is handled with the same caution as other chemotherapy agents. But unlike its parent cisplatin — which IARC classifies as probably carcinogenic (Group 2A) — carboplatin has not been classified by IARC as a carcinogen. So it should not be labelled a Group 2A carcinogen; the caution around it is based on its genotoxicity and hazardous-drug status, not a carcinogen classification.
Why does it matter in the bedroom?
Because patients excrete it. As with the other platinum drugs, it is cleared in urine for days after treatment, and hospital studies find antineoplastic drugs on patient-area surfaces — highest on bathroom floors, tied to handling urine — and reaching people through that contamination. Critically, changing the sheets or making the bed of a treated patient is one of the strongest predictors of picking these drugs up. In a home, that task falls to a family caregiver.
What should a caregiver do?
Follow the home-chemotherapy precautions from your care team, generally for about a week after each dose. Wear disposable gloves when handling soiled bedding, clothing or body fluids; launder contaminated linens separately with an extra rinse; close the toilet lid before flushing and clean bathroom surfaces; and wash hands afterward. The aim is to keep a caregiver's incidental exposure as low as reasonably achievable while the patient gets a vital treatment.
Related compounds
Embr is a sleep environment company researching and addressing the chemistry of the bedroom. Research and product development in progress. This page is informational and is not medical advice; follow your care team's guidance.
Last reviewed 2026-06-27. If you find a factual error, contact us.